• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在患有系统性高血压和轻度稳定型心绞痛的患者中,用钙通道阻滞剂替代β受体阻滞剂加噻嗪类利尿剂治疗时,血压、心输出量、外周阻力及运动表现的反应。

Response of blood pressure, cardiac output, peripheral resistance, and exercise performance to substitution of calcium blocker for beta-blocker plus thiazide diuretic therapy in patients with both systemic hypertension and mild stable angina.

作者信息

Kawanishi D T, Reid C L, Gonzales A, O'Rourke R A, Rahimtoola S H

机构信息

Department of Medicine, LAC-USC Medical Center, University of Southern California School of Medicine 90033.

出版信息

Circulation. 1989 Dec;80(6 Suppl):IV162-70.

PMID:2574640
Abstract

We studied 14 patients to determine whether sustained-release diltiazem is a satisfactory long-term substitute for the combination of propranolol plus hydrochlorothiazide (HCTZ), control phase, in the treatment of systemic hypertension with coexisting chronic stable angina pectoris. All patients had either one- or two-vessel coronary disease and normal left ventricular systolic function. Measurements were made during the control phase and 4 and 8 weeks after substitution of sustained-release diltiazem. Only the sitting blood pressure was available before the control phase (pretreatment). Blood pressure and heart rate were measured with patients supine, sitting, and 5 minutes after standing. Cardiac output was measured in the supine position using a computerized Doppler system, and stroke volume, mean arterial pressure, and total systemic resistance were calculated. Symptom-limited modified Bruce protocol treadmill tests were performed to determine time to onset of 1 mm ST segment depression, time to termination of exercise, reason for cessation of exercise, and maximum rate-pressure product. The patients were initially receiving 160-240 mg/day of propranolol (40-60 mg q.i.d.) plus 25-50 mg/day of HCTZ and, subsequently, 12 of 14 had substitution with 240 mg/day (120 mg b.i.d.) of sustained-release diltiazem, and two received 360 mg/day with one of these patients also receiving 50 mg/day of HCTZ. These patients are a subset of a larger group of patients in whom the response of blood pressure alone has been previously reported. Diltiazem resulted in reduction of blood pressure equivalent to that with the propranolol plus HCTZ combination.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

我们研究了14例患者,以确定缓释地尔硫䓬是否是普萘洛尔加氢氯噻嗪(HCTZ)联合用药(对照阶段)在治疗合并慢性稳定型心绞痛的系统性高血压时令人满意的长期替代药物。所有患者均患有单支或双支冠状动脉疾病且左心室收缩功能正常。在对照阶段以及替换为缓释地尔硫䓬后的4周和8周进行测量。对照阶段(预处理)前仅可获得坐位血压。在患者仰卧位、坐位以及站立5分钟后测量血压和心率。使用计算机化多普勒系统在仰卧位测量心输出量,并计算每搏输出量、平均动脉压和总全身阻力。进行症状限制的改良布鲁斯方案跑步机试验,以确定出现1毫米ST段压低的时间、运动终止时间、运动停止原因以及最大速率 - 压力乘积。患者最初接受160 - 240毫克/天的普萘洛尔(40 - 60毫克,每日4次)加25 - 50毫克/天的HCTZ,随后,14例中有12例替换为240毫克/天(120毫克,每日2次)的缓释地尔硫䓬,2例接受360毫克/天,其中1例患者还接受50毫克/天的HCTZ。这些患者是先前已报告仅血压反应的较大患者群体的一个子集。地尔硫䓬导致的血压降低与普萘洛尔加HCTZ联合用药相当。(摘要截短为250字)

相似文献

1
Response of blood pressure, cardiac output, peripheral resistance, and exercise performance to substitution of calcium blocker for beta-blocker plus thiazide diuretic therapy in patients with both systemic hypertension and mild stable angina.在患有系统性高血压和轻度稳定型心绞痛的患者中,用钙通道阻滞剂替代β受体阻滞剂加噻嗪类利尿剂治疗时,血压、心输出量、外周阻力及运动表现的反应。
Circulation. 1989 Dec;80(6 Suppl):IV162-70.
2
Efficacy and safety of sustained-release diltiazem as replacement therapy for beta blockers and diuretics for stable angina pectoris and coexisting essential hypertension: a multicenter trial.缓释地尔硫䓬作为β受体阻滞剂和利尿剂的替代疗法用于稳定型心绞痛和并存原发性高血压的疗效及安全性:一项多中心试验
Am J Cardiol. 1987 Dec 14;60(17):29I-35I. doi: 10.1016/0002-9149(87)90456-5.
3
Antianginal response to once-daily diltiazem CD in patients receiving concomitant beta-blockers, long-acting nitrates, or both. Diltiazem CD Study Group.接受β受体阻滞剂、长效硝酸盐类药物或两者联合治疗的患者,每日一次服用缓释地尔硫䓬的抗心绞痛反应。地尔硫䓬缓释片研究组。
Pharmacotherapy. 1997 Jul-Aug;17(4):760-6.
4
[Effectiveness of various combination therapies in patients with coronary heart disease].[各种联合治疗对冠心病患者的疗效]
Herz. 1990 Dec;15(6):399-409.
5
Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.稳定性心绞痛伴高血压的治疗:新型美托洛尔制剂(控释片)与硝苯地平之间的良好相互作用
Cardiologia. 1996 Jul;41(7):635-43.
6
Comparison of diltiazem, nitrendipine, and their combination for systemic hypertension and stable angina pectoris.
J Cardiovasc Pharmacol. 1991;18 Suppl 9:S73-6.
7
Effect of diuretic therapy on exercise capacity in patients with chronic angina and preserved left ventricular function.
J Cardiovasc Pharmacol. 2007 May;49(5):275-9. doi: 10.1097/FJC.0b013e3180385ad7.
8
Hemodynamics and exercise tolerance after bisoprolol, nifedipine, and their combination in patients with angina pectoris.比索洛尔、硝苯地平及其联合用药对心绞痛患者血流动力学和运动耐量的影响
J Cardiovasc Pharmacol. 1990;16 Suppl 5:S201-7.
9
Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.新型代谢调节剂雷诺嗪对接受β受体阻滞剂或地尔硫䓬治疗的心绞痛患者运动耐量的影响。
J Cardiovasc Pharmacol. 1992 Jul;20(1):131-8.
10
Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs.使用缓释钙通道阻滞剂治疗心绞痛和高血压。
Circulation. 1987 Jun;75(6 Pt 2):V110-3.